Aaron D. Levine is Associate Dean for Research and Outreach in the Ivan Allen College of Liberal Arts and Professor in the School of Public Policy at Georgia Tech. He also holds an appointment as a Guest Researcher in the Division of Reproductive Health at the Centers for Disease Control and Prevention. He is a member of the leadership team for the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), leading ethics and policy research for the center. He seved as Co-Director for CMaT's Engineering Workforce Development activities from 2017 to 2022. His research focuses on the intersection between public policy and bioethics. Much of his work has examined the development of stem cell science, particularly research using human embryonic stem cells, and the translation of novel cell therapies. He also writes extensively on the oversight of contentious areas of medicine, such as assisted reproductive technology. In 2012, he received a NSF CAREER award to examine the impact of ethical controversy on graduate science education and the development of scientific careers.  He serves as Vice-Chair for Bioethics on the International Society for Cell & Genel Therapy’s Committee on the Ethics of Cell and Gene Therapy and recently completed a three-year term as an elected member of the Board of Directors of the American Society for Bioethics and Humanities. He is also a long-time member of the International Society for Stem Cell Research, the Association for Public Policy Analysis and Management, and the American Association for the Advancement of Science.

Aaron has a long-standing interest in science communication and is the author of Cloning: A Beginner's Guide (Oneworld Publications, 2007), an accessible introduction to the science of cloning and embryonic stem cells and the ethical and policy controversies this science inspires. He was an AAAS Leshner Leadership Institute Public Engagement Fellow for 2019-2020. You can follow Aaron on twitter at @aarondlevine.

He completed his Ph.D. in Public Affairs at Princeton University, where his dissertation research examined the impact of public policy on the development of human embryonic stem cell science.  He also holds an M. Phil. from the University of Cambridge, where, as a Churchill Scholar, he studied computational biology at the Sanger Centre and developed algorithms to help analyze the human genome sequence, and a B.S. in Biology from the University of North Carolina at Chapel Hill, where he was a Morehead Scholar.

Michelle C. LaPlaca, Ph.D. is an Associate Professor in the Department of Biomedical Engineering, a joint department between Georgia Tech and Emory University. Dr. LaPlaca earned her undergraduate degree in Biomedical Engineering from The Catholic University of America, Washington, DC, in 1991 and her M.S.E. (1992) and Ph.D. (1996) in Bioengineering from the University of Pennsylvania, Philadelphia, PA, in the area of neuronal injury biomechanics. Following post-doctoral training in Neurosurgery at the University of Pennsylvania’s Head Injury Center from 1996-98, she joined the faculty at Georgia Tech. Dr. LaPlaca’s research interests are in neurotrauma, specifically: traumatic brain injury, injury biomechanics, cell culture modeling of traumatic injury, neural tissue engineering, and cognitive impairment associated with brain injury and aging. Her research is funded by NIH, NSF, and the Coulter Foundation.

Kim joined the Woodruff School of Mechanical Engineering as an Assistant Professor in July 2013. Prior to his current appointment, he was a Postdoctoral Associate in the David H. Koch Institute for Integrative Cancer Research at MIT, where he developed biomimetic microsystems for probing nanoparticle behaviors in the inflamed endothelium and for synthesizing therapeutic and diagnostic nanomaterials. His doctorate research at CMU focused on closed-loop microfluidic control systems for lab-on-a-chip applications to biochemistry and developmental biology. Prior to his Ph.D., he was a researcher in areas of dynamics, controls, and robotics at R&D Divisions of Hyundai-Kia Motors and Samsung Electronics for six years.

Dr. Keeling earned his medical degree at the University of Louisville in 2001, did his general surgery residency at the University of South Florida School of Medicine from 2001-2008, and completed his cardiothoracic surgery fellowship at Emory in 2011. Dr. Keeling directs the cardiothoracic surgery program at Grady Memorial Hospital and provides clinical service at Emory University Hospital Midtown. His clinical interests include reoperative cardiac surgery, valve repair and thoracic aortic pathology, and his research focuses on clinical trials as well as data-driven investigations of adult cardiac surgical sub-populations.

Dr. Jang’s lab uses multi-disciplinary approaches to study muscle stem cell biology and develops bioactive stem cell delivery vehicles for use in regenerative medicine. Dr. Jang’s lab studies both basic aspects of muscle stem cell biology, especially systemic/metabolic regulations of stem cell and stem cell niche, as well as more translational aspects of muscle stem cell and mesenchymal stem cell for use in therapeutic approaches for musculoskeletal aging, neuromuscular diseases, and traumatic injuries.

Dr. Yuhang Hu Joined the Woodruff School of Mechanical Engineering and the School of Chemical and Biomolecular Engineering at Georgia Institute of Technology as an assistant professor in August 2018. Prior to that, Dr. Hu was an assistant professor in the Department of Mechanical Science and Engineering at University of Illinois at Urbana-Champaign from 2015 to 2018. She received her Ph.D. from Harvard University in the area of Solid Mechanics. She worked in the area of Materials Chemistry as a post-doctoral fellow at Harvard from 2011 to 2014.

Robert E. Guldberg is the DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact and Vice President of the University of Oregon. Guldberg’s research is focused on musculoskeletal mechanobiology, regenerative medicine, and orthopaedic medical devices. Over his 25+ year academic career, Dr. Guldberg has produced over 280 peer-reviewed publications, served as an advisor and board member for numerous biotechnology companies, and co-founded six start-ups. He was previously executive director of the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech from 2009-2018. In 2018, he was selected from a national search to lead the Knight Campus as its inaugural permanent Executive Director, where he has led the creation of its strategic plan, hired faculty into the campus’ first building opened in 2020, and launched the University of Oregon’s first ever engineering degree program. In 2021, he led the launch of Phase 2 of the Knight Campus development with the announcement of a second $500 million gift from Phil and Penny Knight. At the national level, Dr. Guldberg is past Chair of the Americas Chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM). He currently serves on the Executive Leadership Council of the Wu Tsai Human Performance Alliance, a $220 million global initiative to promote wellness and peak performance through scientific discovery and innovation. Dr. Guldberg is an elected fellow of TERMIS, the American Society of Mechanical Engineers (ASME), the American Institute for Medical and Biological Engineering (AIMBE), the Orthopaedic Research Society (ORS), and the National Academy of Inventors (NAI).

Dr. Gross’s research interests include: restorative approaches (including cell and gene therapy) for Parkinson's disease and other neurodegenerative disorders; physiology of movement disorders (Parkinson's disease, tremor, dystonia); novel surgical techniques for epilepsy (e.g. deep brain stimulation, cell and gene therapy). In particular, he has been elucidating the role of axon guidance molecules in the development and reconstruction of the nigrostriatal pathway, which degenerates in P.D. This approach, which encompasses molecular and cellular engineering in combination with neurotransplantation, may be generally useful in reconstructive approaches for many types of nervous system degeneration and injury. 

In July of 2007, Dr. Gross, along with Steve M. Potter, Ph.D. of the Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, was the recipient of a prestigious grant from The Epilepsy Research Foundation (ERF) for translational research funding awards supporting innovative epilepsy products. The grant supports the development of a novel electrical stimulation approach that directly controls the activity of the brain to attain a more stable state from which seizures will not arise.

Rudolph (Rudy) L. Gleason began at Tech in Fall 2005 as an assistant professor. Prior, he was a postdoctoral fellow at Texas A&M University. He is currently a professor in the School of Mechanical Engineering and the School of Biomedical Engineering in the College of Engineering. Gleason’s research program has two key and distinct research aims. The first research aim is to quantify the link between biomechanics, mechanobiology, and tissue growth and remodeling in diseases of the vasculature and other soft tissues. The second research aim is to translate engineering innovation to combat global health disparities and foster sustainable development in low-resource settings around the world. Gleason serves as a Georgia Tech Institute for People and Technology initiative lead for research activities related to global health equity and wellbeing.

Faces of Research - Profile Article